NLSP - Balance Sheet - NLS Pharmaceutics AG

Current Liabilities	7.92 M
Accounts Payable	4.63 M
Short-Term Debt	1.63 M
Other Current Liabilities	1.65 M
Non-Current Liabilities	2.76 M
Long-Term Debt	0
Other Non-Current Liabilities	2.76 M

Millions

	Dec-2023	Dec-2022	Dec-2021	Dec-2020	Dec-2019	Dec-2018	Dec-2017
ASSETS
Cash & Cash Equivalents	0.9	8.9	5.4	93.7 K	0.2	6.68 K	2.2
Short Term Investments	0	0	0	0	0	0	0
Receivables	10.7 K	0	0	0	75.4 K	36.9 K	0
Inventory	0	41.2 K	38.6 K	61.2 K	0	9.36 K	0
Other Current Assets	0.9	0.2	0.2	14.4 K	15.1 K	46.6 K	2.63 K
Total Current Assets	1.8	9.2	5.7	0.2	0.4	90.2 K	2.3
PP&E	6.69 K	18.1 K	29.5 K	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Goodwill	0	0	0	0	0	0	0
Long Term Investments	0	0	0	68 K	54.5 K	55.5 K	0
Other Long Term Assets	16.9 K	12.1 K	12 K	0.9	0.3	1	14.4 K
Other Assets	0	0	1	1	0	0	0
Total Assets	1.8	9.3	5.8	1.2	0.7	0.1	2.3
LIABILITIES
Accounts Payable	4.6	2.4	1.7	4.0	2.5	1.1	0.6
Short Term Debt	1.6	0	0	1.8	0.7	0.7	0
Other Current Liabilities	1.7	1.0	0.7	1.4	0.8	0.6	0.4
Total Current Liabilities	7.9	3.4	2.4	7.2	4.0	2.4	1.0
Long Term Debt	0	0	0	0.3	0.2	6.4	8.9
Deferred Tax Income	0	0	0	0	0	0	0
Other Liabilities	0.3	0.1	0.3	0.2	0.2	0.2	0.1
Total Liabilities	10.7	6.0	5.2	10.2	6.9	9.0	10.0
EQUITY
Common Stock	0.7	0.7	0.3	0.1	0.1	0.1	0.1
Retained Earnings	(70.4)	(58.2)	(41.7)	(29.8)	(26.9)	(21.5)	(16.3)
Other Accumulative Comprehensive Income/Loss	(0.2)	50.8 K	(0.2)	19.4 K	18.7 K	11.3 K	9.99 K
Total Equity	(8.8)	3.3	0.5	(9.0)	(6.2)	(8.8)	(7.7)
Total Liabilities and Equity	1.8	9.3	5.8	1.2	0.7	0.1	2.3
SHARES OUTSTANDING
Common Shares Outstanding	38.2	19.7	14.7	4.8	11.1	11.8	11.8

Free